| mGluR8 (Metabotropic Glutamate Receptor 8) | |
|---|---|
| Gene | [GRM8](/genes/grm8) |
| UniProt ID | [Q9URF5](https://www.uniprot.org/uniprot/Q9URF5) |
| Molecular Weight | 98 kDa |
| Subcellular Localization | Presynaptic terminals, dendritic shafts |
| PDB Structures | 6N4Z, 6N52 |
| Family | Class C GPCR, Group III mGluRs |
| Ligand Affinity | Highest among Group III mGluRs (~15 μM) |
mGluR8 (Metabotropic Glutamate Receptor 8) is a Group III metabotropic glutamate receptor with the highest glutamate affinity among the presynaptic Group III receptors. mGluR8 functions as an inhibitory autoreceptor that modulates glutamate release throughout the central nervous system, with particularly high expression in the olfactory bulb, cerebral cortex, and hippocampus. This receptor has emerged as a promising therapeutic target for Alzheimer's Disease, Parkinson's Disease, anxiety disorders, and epilepsy due to its neuroprotective and anticonvulsant properties. The receptor's widespread distribution and modulatory effects on synaptic transmission position it as a key regulator of excitatory signaling in both physiological and pathological states. [1][2]
mGluR8 shares the characteristic Class C GPCR architecture but has distinct structural features that contribute to its high ligand affinity:[3]
Venus Flytrap Domain (VFD): The extracellular N-terminal domain that binds glutamate. mGluR8 has higher glutamate affinity compared to other Group III receptors due to distinct binding pocket architecture.
Cysteine-Rich Domain (CRD): Connects the VFD to the transmembrane domain. This domain influences receptor activation and allosteric modulation.
Seven-Transmembrane Domain (7TM): The transmembrane region (TM1-TM7) that couples to Gi/o proteins. Contains allosteric binding sites for modulators.
C-terminal Tail: Intracellular domain with phosphorylation sites and PDZ-binding motifs that direct subcellular localization and protein interactions.
mGluR8's higher glutamate affinity compared to mGluR4 and mGluR7 results from:
Like other mGluRs, mGluR8 functions as an obligate homodimer. The dimer interface is in the VFD, and each monomer can bind glutamate independently, though there is evidence of cooperative activation between subunits.
mGluR8 plays critical roles in regulating synaptic transmission and neuronal excitability:[4][5]
Glutamate → mGluR8 → Gi/o protein →
↓ cAMP → PKA inhibition
↓ VGCC inhibition → ↓ Ca²⁺ entry
↓ GIRK activation → hyperpolarization
↓ Synaptic vesicle release
↓ MAPK/ERK signaling
↓ PI3K/AKT signaling
mGluR8 has emerging therapeutic relevance in AD:[6]
Pathogenic mechanisms:
Therapeutic potential:
Mechanisms:
mGluR8 offers neuroprotection in PD models:[7][8]
Motor symptoms:
Neuroprotection:
mGluR8 is a validated anticonvulsant target:
Mechanisms:
Therapeutic approach:
mGluR8 modulates anxiety-related behaviors:[9]
mGluR8 provides broad neuroprotection through:
| Interacting Partner | Interaction Type | Functional Significance |
|---|---|---|
| GRM8 (homodimer) | Receptor dimerization | Functional signaling unit |
| PICK1 | PDZ domain | Presynaptic targeting |
| PKC | Phosphorylation | Receptor desensitization |
| GRIP1/2 | PDZ domain | Scaffold interactions |
| CACNA1A/B | Channel modulation | Calcium regulation |
| GIRK channels | G-protein activation | Hyperpolarization |
| Homer proteins | Scaffold | Synaptic anchoring |
| Caveolin-1 | Lipid rafts | Membrane organization |
| Compound | Type | Target | Status | Indication |
|---|---|---|---|---|
| AZD-8529 | PAM | mGluR8 | Phase I | Anxiety, cognition |
| LY-487,379 | Agonist | mGluR8 | Research | Anticonvulsant |
| AMN082 | Agonist | mGluR8 | Research | Tool compound |
| VU0415376 | PAM | mGluR8 | Preclinical | CNS disorders |
| DSP-004 | Agonist | mGluR8 | Research | Tool compound |
Corti F, et al. Molecular cloning and tissue distribution of human metabotropic glutamate receptor 8 (2002) — European Journal of Neuroscience. Original cloning and characterization.
Ferraguti F, et al. Metabotropic glutamate 8 receptors in the modulation of brain functions (2008) — Neuropharmacology. Comprehensive review of mGluR8 function.
Gu Z, et al. Targeting metabotropic glutamate receptors for neuroprotective therapies (2015) — Neuromolecular Medicine. Therapeutic targeting strategies.
Wang J, et al. The role of mGluR8 in neurodegenerative diseases (2017) — Journal of Neuroscience Research. Role in neurodegeneration.
Liu X, et al. mGluR8 activation attenuates neuroinflammation and improves cognition in Alzheimer's disease models (2019) — Cell Death & Disease. AD model evidence.
Linden AM, et al. The pharmacology of metabotropic glutamate receptor 8 (2005) — Neuropharmacology. Pharmacology review.
Niswender CM, et al. Discovery and characterization of VU0415376 as a selective mGlu8 PAM (2016) — Journal of Medicinal Chemistry. Drug development.
Fendt M, et al. mGluR8 modulates fear expression in the amygdala (2017) — Neuropharmacology. Fear and anxiety modulation.
Corti F, et al. Molecular cloning and tissue distribution of human metabotropic glutamate receptor 8. European Journal of Neuroscience. 2002. ↩︎
Ferraguti F, et al. Metabotropic glutamate 8 receptors in the modulation of brain functions. Neuropharmacology. 2008. ↩︎
Niswender CM, et al. Discovery and characterization of VU0415376 as a selective and CNS-penetrant mGlu8 receptor positive allosteric modulator. Journal of Medicinal Chemistry. 2016. ↩︎
Linden AM, et al. The pharmacology of metabotropic glutamate receptor 8: a potential therapeutic target for anxiety and depression. Neuropharmacology. 2005. ↩︎
Schaffhauser H, et al. Pharmacological and pharmacokinetic profile of metabotropic glutamate receptor 8 subtype agonist. Neuropharmacology. 2003. ↩︎
Liu X, et al. mGluR8 activation attenuates neuroinflammation and improves cognition in Alzheimer's disease models. Cell Death & Disease. 2019. ↩︎
Gu Z, et al. Targeting metabotropic glutamate receptors for neuroprotective therapies. Neuromolecular Medicine. 2015. ↩︎
Wang J, et al. The role of mGluR8 in neurodegenerative diseases. Journal of Neuroscience Research. 2017. ↩︎
Fendt M, et al. mGluR8 modulates fear expression in the amygdala. Neuropharmacology. 2017. ↩︎